Abstract
Several studies showed the inaccuracy of classical surrogate endpoints, such as progression-free survival (PFS) and objective response rate (ORR), in predicting overall survival (OS) in trials of ICI. Patients that respond to immunotherapy have longer median duration of response (mDR) than those that achieve an ORR with standard CT. We aimed to explore the validity of new surrogate endpoints that take into account ORR and mDR in the context of combination ICI trials.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
